A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)

Inclusion Criteria: * Signed and dated informed consent has been obtained * Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs and/or trunk. The lesions must have a total size suitable for application of 6 different products. * Age 18 years or above * Outpatients * Female subjects must be of either * non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus or has tubal ligation) or, * child-bearing potential provided there is a confirmed negative pregnancy test prior to trial treatment to rule out pregnancy. Exclusion Criteria: * Female subjects who are breast feeding * Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation: * Etanercept - within 4 weeks prior to randomisation and during the trial * Adalimumab, infliximab - within 8 weeks prior to randomisation and during the trial * Ustekinumab - within 16 weeks prior to randomisation and during the trial * Other products - within 4 weeks/5 half-lives prior to randomisation and during the trial (whichever is longer) * Systemic treatment with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within the 4-week period prior to randomisation and during the trial, * Subjects using phototherapy within…